Medical company Fluxergy LLC revealed on Monday that it is seeking Fluxergy LLC Emergency Use Authorization (EUA) approval under the US Food and Drug Administration (FDA) Center For Devices and Radiological Health for use of its one-hour COVID-19 test at POC.
This authorisation would permit medical professionals to begin using the company's high-speed Research Use Only (RUO) test system as a COVID-19 diagnostic at the point-of-care (POC). The Fluxergy Analyzer and the single-use consumable Fluxergy Cards are designed to be very cost-effective and scalable, using proprietary printed circuit board (PCB) manufacturing and microfluidics technologies.
According to the company, its Fluxergy Analyzer system has accurately identified the SARS-CoV-2 virus in under one hour in bench lab tests and in follow-up validation tests at University of California San Diego. The validation was led by Dr Davey Smith, professor of Medicine and head of the UCSD Division of Infectious Diseases and Global Public Health and member of Fluxergy Medical Advisory board.
Advanced rapid point-of-care PCR tests for COVID-19, including the company's Fluxergy Analyzer system, may have the potential to save significant time compared to standard lab tests that must be shipped to centralized laboratories for processing.
The company's on-site sample-to-answer test for COVID-19 requires a very small sample, typically a nasal swab. This swab is mixed with a reagent solution, loaded onto the Fluxergy card and inserted into the Fluxergy Analyzer in a convenient two-step procedure.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial